0001415889-11-000966.txt : 20111103 0001415889-11-000966.hdr.sgml : 20111103 20110912153808 ACCESSION NUMBER: 0001415889-11-000966 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ChromaDex Corp. CENTRAL INDEX KEY: 0001386570 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 262940963 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 10005 MUIRLANDS BLVD. STREET 2: STE. G, FIRST FLOOR CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-419-0288 MAIL ADDRESS: STREET 1: 10005 MUIRLANDS BLVD. STREET 2: STE. G, FIRST FLOOR CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: CODY RESOURCES, INC. DATE OF NAME CHANGE: 20070112 CORRESP 1 filename1.htm CHROMADEX CORPORATION - FORM correspondence

ChromaDex Corporation

10005 Muirlands Boulevard, Suite G

Irvine, California 92618


September 12, 2011


VIA FACSIMILE AND EDGAR


Division of Corporation Finance

U.S. Securities and Exchange Commission

Washington, D.C. 20549


Re:

ChromaDex Corporation
Preliminary Proxy Statement


Filed August 29, 2011

Registration No. 000-53290

Dear Sir or Madam:

With respect to the above-referenced Preliminary Proxy Statement, ChromaDex Corporation (the “Company”) acknowledges that:

·

should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

·

the action of the Commission or the staff, acting pursuant to delegated authority in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

·

the Company may not assert the staff comments and the declaration of the effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

The Company confirms that it is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the above-referenced Preliminary Proxy Statement.

We request that we be notified of conclusion of the Commission’s review by letter to Matthew O’Loughlin of Manatt, Phelps & Phillips, LLP.

Sincerely,


CHROMADEX CORPORATION


By: /s/ TOM VARVARO

       Tom Varvaro

       Chief Financial Officer